Correlations between maternal hepatitis B virus carrier status and Down's syndrome prenatal screening indicators and their effects on the screening results

• Published in: Journal of obstetrics and gynaecology 2022-10, Vol.42 (7), p.2793-2798
• Main Authors: Huang, Lingling, Chen, Yiming, Ning, Wenwen, Chen, Yijie, Yu, Daojun
• Format: Article
• Language: English
• Subjects: Alpha-fetoprotein; alpha-Fetoproteins - metabolism; Biomarkers; Chorionic Gonadotropin; Chorionic Gonadotropin, beta Subunit, Human; Down Syndrome - diagnosis; Down's syndrome; Female; Gallbladder diseases; Hepatitis B; Hepatitis B virus; hepatitis B virus carrier; Humans; odds ratio; Pregnancy; Pregnancy Trimester, First; pregnancy-associated plasma protein A; Pregnancy-Associated Plasma Protein-A - analysis; Prenatal Diagnosis - methods; prenatal screening; Regression analysis; Retrospective Studies
• ISSN: 0144-3615; 1364-6893
• DOI: 10.1080/01443615.2022.2109409

The aim of this study was to determine the correlation between maternal hepatitis B virus (HBV) carrier status and pregnancy-associated serum screening indicators, as well as their implications on the prenatal screening results of Down's syndrome (DS). This retrospective cohort study included two groups, namely the healthy gravidas group (n = 19804) and the maternal HBV carrier group (n = 792). Serum pregnancy-associated plasma protein A (PAPP-A), alpha-fetoprotein (AFP), and free beta subunit of human chorionic gonadotropin (free β-hCG) levels, as well as the foetal nuchal translucency (NT) thickness, were measured. Multivariatebinary logistic regression analysis was used to evaluate the association between the HBV carrier status and prenatal screening biomarkers. The PAPP-A multiple of the medium (MoM) and free β-hCG MoM in the first trimester were significantly higher in the HBV carrier group than in the control group (both P